Article info

Download PDFPDF

THU0043 Autoantibody profiling in prostvac and ipilimumab treated prostate cancer patients reveals potential biomarkers of immune-related adverse events
Free

Authors

Citation

Budde P, Marte J, Zucht H, et al
THU0043 Autoantibody profiling in prostvac and ipilimumab treated prostate cancer patients reveals potential biomarkers of immune-related adverse events

Publication history

  • First published June 12, 2018.
Online issue publication 
June 12, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.